UGT1A1 and neoplasm: Six (15%) patients (UGT1A1 wild‐type [n = 2] and heterozygous [n = 4]) showed objective responses, including partial response (n = 1), tumor shrinkage (n = 4), and improved findings on their MIBG scan (n = 1).